Authors
Daniel H Solomon, Robert J Glynn, Elizabeth W Karlson, Fengxin Lu, Cassandra Corrigan, Josh Colls, Chang Xu, Jean MacFadyen, Medha Barbhaiya, Nancy Berliner, Paul F Dellaripa, Brendan M Everett, Aruna D Pradhan, Sarah P Hammond, Meredith Murray, Deepak A Rao, Susan Y Ritter, Anna Rutherford, Jeffrey A Sparks, Jackie Stratton, Dong H Suh, Sara K Tedeschi, Kathleen MM Vanni, Nina P Paynter, Paul M Ridker
Publication date
2020/3/17
Journal
Annals of internal medicine
Volume
172
Issue
6
Pages
369-380
Publisher
American College of Physicians
Description
Background
Low-dose methotrexate (LD-MTX) is the most commonly used drug for systemic rheumatic diseases worldwide and is the recommended first-line agent for rheumatoid arthritis. Despite extensive clinical use for more than 30 years, few data on adverse event (AE) rates derive from randomized, placebo-controlled trials, where both causality and magnitude of risk can be inferred.
Objective
To investigate AE rates, risk, and risk differences comparing LD-MTX versus placebo.
Design
Prespecified secondary analyses of a double-blind, placebo-controlled, randomized trial. (ClinicalTrials.gov: NCT01594333)
Setting
North America.
Participants
Adults with known cardiovascular disease and diabetes or metabolic syndrome.
Intervention …
Scholar articles
DH Solomon, RJ Glynn, EW Karlson, F Lu, C Corrigan… - Annals of internal medicine, 2020
D Solomon, R Glynn, E Karlson, F Lu, C Corrigan… - ARTHRITIS & RHEUMATOLOGY, 2019